Valuation : Interpace Biosciences, Inc.

Market Cap 3.87Cr 3.33Cr 3.12Cr 2.86Cr 5.33Cr 365.55Cr 5.37Cr 37Cr 14Cr 186.81Cr 15Cr 14Cr 601.65Cr P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 3.73Cr 3.21Cr 3.02Cr 2.76Cr 5.15Cr 353.06Cr 5.19Cr 36Cr 14Cr 180.43Cr 14Cr 14Cr 581.09Cr EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day-6.73%
1 week-14.54%
Current month-14.00%
1 month-18.11%
3 months-25.60%
6 months-27.59%
Current year+5.84%
1 week 6.45
Extreme 6.45
7.8
1 month 6.45
Extreme 6.45
8.5
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
51.65
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Exercice

Chief Financial Officer

13,85,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-6.73%-14.54%+64.81%+35.62% 3.87Cr
+0.22%-3.79%+94.52%+448.34% 4.69TCr
-0.16%-1.95%+20.50%+61.39% 2.69TCr
+3.04%-3.79%-18.74%-40.06% 663.74Cr
-2.78%-2.32%+3.75%+136.38% 595.74Cr
+0.47%-0.58%+15.36%+77.39% 338.86Cr
+0.22%-2.73%-31.77%+1,886.38% 258.62Cr
+1.01%-5.90%+114.16%+23.61% 223.55Cr
+7.17%+6.83%+30.00%+35.64% 209.42Cr
-2.60%-5.64%-13.69%-55.31% 183.43Cr
Average -0.01%-1.65%+27.89%+260.94% 985.4Cr
Weighted average by Cap. +0.27%-3.22%+52.21%+288.01%

Financials

2024 2025
Net sales 4.69Cr 4.04Cr 3.79Cr 3.47Cr 6.47Cr 443.59Cr 6.52Cr 45Cr 17Cr 226.69Cr 18Cr 17Cr 730.1Cr 3.87Cr 3.33Cr 3.13Cr 2.86Cr 5.34Cr 366.1Cr 5.38Cr 37Cr 14Cr 187.09Cr 15Cr 14Cr 602.55Cr
Net income 67.02L 57.66L 54.11L 49.51L 92.41L 63Cr 93.14L 6.4Cr 2.49Cr 32Cr 2.52Cr 2.46Cr 104.27Cr 2.46Cr 2.11Cr 1.98Cr 1.82Cr 3.39Cr 232.31Cr 3.42Cr 23Cr 9.14Cr 118.72Cr 9.23Cr 9.03Cr 382.35Cr
Net Debt 43.95L 37.81L 35.49L 32.47L 60.6L 42Cr 61.08L 4.2Cr 1.63Cr 21Cr 1.65Cr 1.61Cr 68Cr -13.22L -11.37L -10.67L -10L -18.23L -12Cr -18.37L -1.26Cr -49.17L -6.39Cr -49.64L -48.56L -21Cr
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
03/26/03 $6.510 -6.73% 9,471
02/26/02 $6.980 -0.29% 5,330
01/26/01 $7.000 -7.53% 23,836
31/26/31 $7.570 -0.63% 5,519
28/26/28 $7.618 +5.08% 2,520

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXGD Stock